Cornerstone Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,500
| Closed | -$2.7M | – | 149 |
|
|
2025
Q4 | $2.7M | Sell |
3,500
-2,500
| -42% | -$1.7M | 0.09% | 144 |
|
|
2025
Q3 | $3.37M | Sell |
6,000
-100
| -2% | -$56.5K | 0.11% | 145 |
|
|
2025
Q2 | $3.2M | Hold |
6,100
| – | – | 0.11% | 148 |
|
|
2025
Q1 | $3.87M | Sell |
6,100
-1,800
| -23% | -$1.24M | 0.17% | 134 |
|
|
2024
Q4 | $5.63M | Buy |
7,900
+1,900
| +32% | +$1.59M | 0.22% | 101 |
|
|
2024
Q3 | $6.31M | Buy |
6,000
+700
| +13% | +$779K | 0.25% | 97 |
|
|
2024
Q2 | $5.57M | Hold |
5,300
| – | – | 0.23% | 109 |
|
|
2024
Q1 | $5.1M | Hold |
5,300
| – | – | 0.21% | 120 |
|
|
2023
Q4 | $4.65M | Sell |
5,300
-2,100
| -28% | -$1.73M | 0.2% | 122 |
|
|
2023
Q3 | $6.09M | Sell |
7,400
-3,700
| -33% | -$2.91M | 0.28% | 93 |
|
|
2023
Q2 | $7.98M | Buy |
11,100
+1,100
| +11% | +$848K | 0.38% | 75 |
|
|
2023
Q1 | $8.22M | Hold |
10,000
| – | – | 0.38% | 64 |
|
|
2022
Q4 | $7.21M | Hold |
10,000
| – | – | 0.36% | 76 |
|
|
2022
Q3 | $6.89M | Hold |
10,000
| – | – | 0.34% | 76 |
|
|
2022
Q2 | $5.91M | Buy |
+10,000
| New | +$6.5M | 0.31% | 85 |
|
|
2022
Q1 | – | Sell |
-2,000
| Closed | -$1.26M | – | 177 |
|
|
2021
Q4 | $1.26M | Hold |
2,000
| – | – | 0.07% | 162 |
|
|
2021
Q3 | $1.21M | Hold |
2,000
| – | – | 0.07% | 160 |
|
|
2021
Q2 | $1.12M | Sell |
2,000
-3,000
| -60% | -$1.52M | 0.07% | 174 |
|
|
2021
Q1 | $2.37M | Sell |
5,000
-3,000
| -38% | -$1.46M | 0.21% | 113 |
|
|
2020
Q4 | $3.87M | Hold |
8,000
| – | – | 0.34% | 75 |
|
|
2020
Q3 | $4.48M | Buy |
8,000
+3,000
| +60% | +$1.82M | 0.4% | 62 |
|
|
2020
Q2 | $3.12M | Buy |
+5,000
| New | +$2.84M | 0.29% | 87 |
|
|
2018
Q3 | – | Sell |
-3,000
| Closed | -$1.03M | – | 232 |
|
|
2018
Q2 | $1.03M | Hold |
3,000
| – | – | 0.13% | 154 |
|
|
2018
Q1 | $1.03M | Sell |
3,000
-2,000
| -40% | -$696K | 0.12% | 168 |
|
|
2017
Q4 | $1.88M | Hold |
5,000
| – | – | 0.21% | 133 |
|
|
2017
Q3 | $2.24M | Buy |
+5,000
| New | +$2.38M | 0.26% | 108 |
|
|
2016
Q2 | – | Sell |
-1,000
| Closed | -$360K | – | 226 |
|
|
2016
Q1 | $360K | Sell |
1,000
-1,000
| -50% | -$412K | 0.09% | 177 |
|
|
2015
Q4 | $1.09M | Hold |
2,000
| – | – | 0.25% | 111 |
|
|
2015
Q3 | $930K | Buy |
+2,000
| New | +$1.07M | 0.22% | 122 |
|
Other funds holding REGN
VCM
N
Cornerstone Advisors's REGN Position: Q1 2026 in Review
Cornerstone Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 3,500 shares — an estimated $2.7M sold.
Cornerstone Advisors first reported a position in REGN in Q3 2015 and held it in 29 quarters. The position peaked at $8.22M in Q1 2023. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Cornerstone Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Cornerstone Advisors sold 3,500 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $2.7M.
- Cornerstone Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2015 and held it in 29 quarters.
- Cornerstone Advisors's Regeneron Pharmaceuticals position peaked at $8.22M in Q1 2023.
- 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Cornerstone Advisors's 13F filing for Q1 2026, filed 8 May 2026.